
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
Mylan Inc. recently announced that its subsidiary, Mylan Pharmaceuticals Inc., has launched alfuzosin hydrochloride extended-release tablets, 10 mg, for signs and symptoms of BPH.
Mylan Inc. recently announced that its subsidiary, Mylan Pharmaceuticals Inc., has launched alfuzosin hydrochloride extended-release tablets, 10 mg, for signs and symptoms of BPH.
The tablets are the generic version of Uroxatral, which had U.S. sales of approximately $241 million for the 12 months ending June 30, 2011, according to IMS Health.





